verapamil has been researched along with Cardiovascular Diseases in 73 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Bergamo Nephrologic Diabetes Complications Trial-B was a multicentre, prospective, double-blind, parallel-group trial comparing renal and cardiovascular outcomes in 281 hypertensive type 2 diabetes patients with microalbuminuria randomized to at least 2-year VeraTran (verapamil/trandolapril 180 mg/2 mg daily) or trandolapril (2 mg daily, identical image) treatment." | 9.15 | Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. ( Bossi, A; Chiurchiu, C; Cravedi, P; Ene-Iordache, B; Fassi, A; Gaspari, F; Gherardi, G; Iliev, IP; Ilieva, A; Motterlini, N; Perna, A; Remuzzi, G; Rubis, N; Ruggenenti, P; Trevisan, R, 2011) |
| "The Bergamo Nephrologic Diabetes Complications Trial-B was a multicentre, prospective, double-blind, parallel-group trial comparing renal and cardiovascular outcomes in 281 hypertensive type 2 diabetes patients with microalbuminuria randomized to at least 2-year VeraTran (verapamil/trandolapril 180 mg/2 mg daily) or trandolapril (2 mg daily, identical image) treatment." | 5.15 | Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. ( Bossi, A; Chiurchiu, C; Cravedi, P; Ene-Iordache, B; Fassi, A; Gaspari, F; Gherardi, G; Iliev, IP; Ilieva, A; Motterlini, N; Perna, A; Remuzzi, G; Rubis, N; Ruggenenti, P; Trevisan, R, 2011) |
| "Based on over 4,000 person-years of observation, patients with acute myocardial infarction (MI) treated with verapamil had a decreased risk of nonfatal reinfarction compared with placebo (relative risk 0." | 4.80 | Verapamil use in patients with cardiovascular disease: an overview of randomized trials. ( Faich, G; Makuch, R; Pepine, CJ, 1998) |
| " Verapamil is extremely effective in patients with supraventricular tachyarrhythmias, hypertrophic cardiomyopathy, and the various anginal syndromes, but it appears to be ineffective or possibly even deleterious in those with pulmonary hypertension, congestive heart failure of any cause, and Raynaud's phenomenon or disease." | 4.77 | Calcium antagonists in patients with cardiovascular disease. Current perspectives. ( Hillis, LD; Winniford, MD, 1985) |
| "Verapamil (VER) is a calcium channel blocker that is widely used to treat various cardiovascular diseases and is also effective in migraine prophylaxis." | 3.91 | Analytical techniques for the determination of verapamil in biological samples and dosage forms: an overview. ( Jouyban, A; Pourkarim, F; Rahimpour, E, 2019) |
| "Verapamil, which has profound electrophysiologic effects on the slow inward current, is emerging as a valuable antiarrhythmic agent." | 3.75 | Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects. ( Antman, EM; Braunwald, E; Muller, JE; Stone, PH, 1980) |
| "In a prospective study of 809 patients with stable angina pectoris randomized to receive metoprolol or verapamil, a subgroup of 69 diabetic patients was compared with non-diabetic patients with respect to the risk of cardiovascular (CV) death, non-fatal myocardial infarction (MI) and revascularization." | 3.73 | The impact of diabetes or elevated fasting blood glucose on cardiovascular prognosis in patients with stable angina pectoris. ( Björkander, I; Forslund, L; Held, C; Hjemdahl, P; Rehnqvist, N, 2005) |
| "Fibrinogen and WBC were independent predictors of CV death or non-fatal MI as well as disease progression leading to revascularization in patients with stable angina pectoris." | 2.69 | Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris. Results from the APSIS study. The Angina Prognosis Study in Stockholm. ( Björkander, I; Forslund, L; Håkan Wallén, N; Held, C; Hjemdahl, P; Rehnqvist, N; Wiman, B, 2000) |
| " Another side effect is constipation, which is frequent after verapamil." | 2.38 | Calcium antagonists--assessment of side effects. ( Thulin, T, 1990) |
| "Verapamil was more often associated with conduction problems (up to 9%) and dyspnea or heart failure (up to 8%)." | 2.37 | Review of the cardiovascular adversity of the calcium antagonist beta-blocker combination: implications for antihypertensive therapy. ( Brouwer, RM; Bühler, FR; Follath, F, 1985) |
| " Diltiazem with a beta-blocker is usually well-tolerated, with a low incidence of adverse effects, similar to the experience with diltiazem monotherapy." | 2.37 | Combined use of calcium-channel and beta-adrenergic blockers for the treatment of chronic stable angina. Rationale, efficacy, and adverse effects. ( Parisi, AF; Strauss, WE, 1988) |
| "Incident cancer events were gathered from a nationwide registry of hospitalisation data and from a specialised cancer centre in the Rotterdam region." | 1.32 | Verapamil is associated with an increased risk of cancer in the elderly: the Rotterdam study. ( Beiderbeck-Noll, AB; Coebergh, JW; Herings, RM; Hofman, A; Leufkens, HG; Stricker, BH; Sturkenboom, MC; van der Linden, PD, 2003) |
| " Dosage levels and corresponding mean trough levels (+/- S." | 1.28 | Requirements for drug monitoring of verapamil: experience from an unselected group of patients with cardiovascular disease. ( Husum, D; Jensen, G; Johnsen, A, 1990) |
| "They also have great potential for the treatment of hypertension, cerebrovascular disorders, and Raynaud's phenomenon." | 1.27 | Calcium channel blocking drugs. Part II: Clinical applications. ( Brill, DM; Fozzard, HA, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 34 (46.58) | 18.7374 |
| 1990's | 16 (21.92) | 18.2507 |
| 2000's | 12 (16.44) | 29.6817 |
| 2010's | 11 (15.07) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pourkarim, F | 1 |
| Rahimpour, E | 1 |
| Jouyban, A | 1 |
| Carvalho, DS | 1 |
| de Almeida, AA | 1 |
| Borges, AF | 1 |
| Vannucci Campos, D | 1 |
| McDonough, CW | 1 |
| Gong, Y | 3 |
| Padmanabhan, S | 1 |
| Burkley, B | 1 |
| Langaee, TY | 2 |
| Melander, O | 1 |
| Pepine, CJ | 5 |
| Dominiczak, AF | 1 |
| Cooper-Dehoff, RM | 2 |
| Johnson, JA | 3 |
| Cerda, A | 1 |
| Hirata, RD | 1 |
| Hirata, MH | 1 |
| Baryshnikova, GA | 1 |
| Chorbinskayva, SA | 1 |
| Stepanova, II | 1 |
| Blochina, OE | 1 |
| Zverkov, IV | 1 |
| Maslovskyi, LV | 1 |
| Korchazhkina, NB | 1 |
| Maslennikova, OM | 1 |
| Beitelshees, AL | 1 |
| Navare, H | 1 |
| Wang, D | 2 |
| Wessel, J | 1 |
| Moss, JI | 1 |
| Sadee, W | 2 |
| Schork, NJ | 1 |
| Sawatzki, M | 1 |
| Kummer, O | 1 |
| Krähenbühl, S | 1 |
| Siegemund, M | 1 |
| Ruggenenti, P | 2 |
| Fassi, A | 1 |
| Ilieva, A | 1 |
| Iliev, IP | 2 |
| Chiurchiu, C | 1 |
| Rubis, N | 2 |
| Gherardi, G | 1 |
| Ene-Iordache, B | 2 |
| Gaspari, F | 2 |
| Perna, A | 2 |
| Cravedi, P | 1 |
| Bossi, A | 2 |
| Trevisan, R | 2 |
| Motterlini, N | 2 |
| Remuzzi, G | 2 |
| Schmidt, M | 1 |
| Johansen, MB | 1 |
| Robertson, DJ | 1 |
| Maeng, M | 1 |
| Kaltoft, A | 1 |
| Jensen, LO | 1 |
| Tilsted, HH | 1 |
| Bøtker, HE | 1 |
| Sørensen, HT | 1 |
| Baron, JA | 1 |
| Pirker, S | 1 |
| Baumgartner, C | 1 |
| Papp, AC | 1 |
| Pinsonneault, JK | 1 |
| Newman, LC | 1 |
| Kumari, M | 1 |
| Hingorani, AD | 1 |
| Talmud, PJ | 1 |
| Shah, S | 1 |
| Humphries, SE | 1 |
| Porrini, E | 1 |
| Ilieva, AP | 1 |
| Dodesini, AR | 1 |
| Sampietro, G | 1 |
| Capitoni, E | 1 |
| Caracciolo, VJ | 1 |
| Shaefer, BM | 1 |
| Charney, P | 1 |
| Beiderbeck-Noll, AB | 1 |
| Sturkenboom, MC | 1 |
| van der Linden, PD | 1 |
| Herings, RM | 1 |
| Hofman, A | 1 |
| Coebergh, JW | 1 |
| Leufkens, HG | 1 |
| Stricker, BH | 1 |
| Held, C | 3 |
| Björkander, I | 2 |
| Forslund, L | 3 |
| Rehnqvist, N | 3 |
| Hjemdahl, P | 3 |
| El Haouari, M | 1 |
| Bnouham, M | 1 |
| Bendahou, M | 1 |
| Aziz, M | 1 |
| Ziyyat, A | 1 |
| Legssyer, A | 1 |
| Mekhfi, H | 1 |
| Almquist, T | 1 |
| Sica, DA | 1 |
| Mancia, G | 1 |
| Messerli, F | 2 |
| Bakris, G | 1 |
| Zhou, Q | 1 |
| Champion, A | 1 |
| Gilani, AH | 1 |
| Bashir, S | 1 |
| Khan, AU | 1 |
| Karlsberg, RP | 3 |
| Ellrodt, AG | 1 |
| Singh, BN | 2 |
| Fossati, C | 1 |
| Guistiniani, S | 1 |
| Ellrodt, G | 1 |
| Chew, CY | 1 |
| Antman, EM | 3 |
| Stone, PH | 2 |
| Muller, JE | 2 |
| Braunwald, E | 2 |
| Fleckenstein, A | 1 |
| Strubelt, O | 1 |
| Rossi, LP | 1 |
| Foster, BC | 1 |
| Tritthart, HA | 1 |
| Assey, ME | 1 |
| Dargie, H | 1 |
| Rowland, E | 1 |
| Krikler, D | 2 |
| Aronow, WS | 1 |
| Chia, BL | 1 |
| Ee, BK | 1 |
| Tan, AT | 1 |
| Choo, M | 1 |
| Schwartz, DJ | 1 |
| Wasserstrom, JA | 1 |
| Fozzard, HA | 2 |
| Hogan, L | 1 |
| Lancelin, B | 1 |
| Blanchard, D | 1 |
| Aziza, JP | 1 |
| Guermonprez, JL | 1 |
| Maurice, P | 1 |
| Kline, JA | 1 |
| Tomaszewski, CA | 1 |
| Schroeder, JD | 1 |
| Raymond, RM | 1 |
| Salerno, SM | 1 |
| Zugibe, FT | 1 |
| Tonkin, A | 1 |
| Frewin, D | 1 |
| Chatelain, P | 1 |
| Mouton, J | 1 |
| Feys, G | 1 |
| Laruel, A | 1 |
| Manning, AS | 1 |
| Conti, CR | 1 |
| Laragh, JH | 1 |
| Pepine, C | 1 |
| Sleight, P | 2 |
| Tuncok, Y | 1 |
| Apaydin, S | 1 |
| Kalkan, S | 1 |
| Ates, M | 1 |
| Guven, H | 1 |
| Black, HR | 1 |
| Elliott, WJ | 2 |
| Neaton, JD | 1 |
| Grandits, G | 1 |
| Grambsch, P | 1 |
| Grimm, RH | 1 |
| Hansson, L | 1 |
| Lacoucière, Y | 1 |
| Muller, J | 1 |
| Weber, MA | 1 |
| White, WB | 1 |
| Williams, G | 1 |
| Wittes, J | 1 |
| Zanchetti, A | 1 |
| Fakouhi, TD | 1 |
| Faich, G | 1 |
| Makuch, R | 1 |
| Håkan Wallén, N | 1 |
| Wiman, B | 1 |
| Tkaczewski, W | 1 |
| Goch, JH | 1 |
| Tam, IM | 1 |
| Wandres, DL | 1 |
| Kaesemeyer, WH | 1 |
| Prisant, LM | 1 |
| Carr, AA | 1 |
| Thulin, T | 1 |
| de la Figuera von Wichmann, M | 1 |
| Scholz, G | 1 |
| Marek, H | 1 |
| Kellner, K | 1 |
| Husum, D | 1 |
| Johnsen, A | 1 |
| Jensen, G | 1 |
| Brouwer, RM | 1 |
| Follath, F | 1 |
| Bühler, FR | 1 |
| Brill, DM | 1 |
| Berman, BA | 1 |
| Ross, RN | 1 |
| Palombo, C | 1 |
| Mian, M | 1 |
| Bertelli, A | 1 |
| Lehtonen, LA | 1 |
| Eskola, JT | 1 |
| Gordin, A | 1 |
| Erkko, MK | 1 |
| Räihä, IJ | 1 |
| Lehtonen, AA | 1 |
| Strauss, WE | 1 |
| Parisi, AF | 1 |
| De Gregorio, G | 1 |
| Restivo, S | 1 |
| De Gregorio, C | 1 |
| Burgess, CD | 1 |
| Larach, DR | 1 |
| Zelis, R | 1 |
| Winniford, MD | 1 |
| Hillis, LD | 1 |
| Bezer, G | 1 |
| Duchêne-Marullaz, P | 1 |
| Lavarenne, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| Qianyangyuyin Formula Prevent and Treat for Early Renal Injury in Hypertensive Patients[NCT04078711] | Phase 2/Phase 3 | 520 participants (Anticipated) | Interventional | 2019-09-10 | Not yet recruiting | ||
| A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT)[NCT00235014] | Phase 4 | 1,204 participants (Actual) | Interventional | 1997-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
21 reviews available for verapamil and Cardiovascular Diseases
| Article | Year |
|---|---|
Treatments for diabetes mellitus type II: New perspectives regarding the possible role of calcium and cAMP interaction.
Topics: Adjuvants, Pharmaceutic; Animals; Calcium; Calcium Channel Blockers; Cardiovascular Diseases; Cyclic | 2018 |
[Use of Verapamil and Dilthiasem in treating patients at high cardiovascular risk (review of literature)].
Topics: Calcium Channel Blockers; Cardiovascular Diseases; Diltiazem; Humans; Verapamil | 2016 |
Clinical applications of slow channel blocking compounds.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Blood Platelets; Blood Vessels; Calcium | 1983 |
[Side-effects of calcium antagonists].
Topics: Calcium Channel Blockers; Cardiovascular Diseases; Drug Hypersensitivity; Drug Interactions; Fendili | 1984 |
Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects.
Topics: Action Potentials; Adenosine Triphosphate; Animals; Arrhythmias, Cardiac; Calcium; Calcium Channel B | 1980 |
History of calcium antagonists.
Topics: Aniline Compounds; Animals; Calcium; Calcium Channel Blockers; Cardiovascular Diseases; Gallopamil; | 1983 |
Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications.
Topics: Benzazepines; Calcium Channel Blockers; Cardiovascular Diseases; Coronary Circulation; Diltiazem; He | 1980 |
Role of calcium antagonists in cardiovascular therapy.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Blood Vessels; Calcium; Calcium Channel Blockers; Cardiomyopa | 1981 |
Re-examining the clinical safety and roles of calcium antagonists in cardiovascular medicine.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium Channel Blockers; Cardiovascular Diseases; Cor | 1996 |
Calcium antagonists and cardiovascular prognosis: a homogeneous group?
Topics: Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Dihydropyridines; Dilti | 1996 |
Verapamil use in patients with cardiovascular disease: an overview of randomized trials.
Topics: Angina Pectoris; Calcium Channel Blockers; Cardiovascular Diseases; Female; Humans; Hypertension; Ma | 1998 |
Calcium-channel blockers and gingival hyperplasia.
Topics: Aged; Calcium Channel Blockers; Cardiovascular Diseases; Diltiazem; Female; Gingival Hyperplasia; Hu | 1992 |
Calcium antagonists--assessment of side effects.
Topics: Benzodiazepines; Calcium Channel Blockers; Cardiovascular Diseases; Dihydropyridines; Health Status; | 1990 |
[Verapamil: a primary care antihypertensive].
Topics: Antihypertensive Agents; Cardiovascular Diseases; Humans; Hypertension; Primary Health Care; Risk Fa | 1990 |
Review of the cardiovascular adversity of the calcium antagonist beta-blocker combination: implications for antihypertensive therapy.
Topics: Adrenergic beta-Antagonists; Calcium Channel Blockers; Cardiovascular Diseases; Diltiazem; Drug Ther | 1985 |
Treating coexisting cardiovascular and pulmonary disease with calcium antagonists.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Asthma, Exercise-Induced; Bronchial Spasm; Calcium; Ca | 1986 |
[Calcium antagonists: accounts on new perspectives of their use and an update on side effects].
Topics: Adult; Animals; Asthma; Calcium Channel Blockers; Cardiovascular Diseases; Diltiazem; Esophageal Ach | 1989 |
Combined use of calcium-channel and beta-adrenergic blockers for the treatment of chronic stable angina. Rationale, efficacy, and adverse effects.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Cardiovascular Diseases; Dil | 1988 |
Advances in calcium blocker therapy.
Topics: Arrhythmias, Cardiac; Arteriosclerosis; Asthma; Blood Platelet Disorders; Calcium; Calcium Channel B | 1986 |
Calcium antagonists in patients with cardiovascular disease. Current perspectives.
Topics: Angina Pectoris; Angina Pectoris, Variant; Atrial Fibrillation; Atrial Flutter; Benzazepines; Cardio | 1985 |
[Recent data on coronary dilators].
Topics: Amino Alcohols; Aminophylline; Animals; Benzofurans; Cardiovascular Diseases; Cats; Coronary Disease | 1968 |
9 trials available for verapamil and Cardiovascular Diseases
| Article | Year |
|---|---|
Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Cardiovasc | 2013 |
Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channe | 2011 |
Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channe | 2011 |
Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channe | 2011 |
Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channe | 2011 |
Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Cardiotonic Agents; Cardiov | 2012 |
Prognostic implications of renal dysfunction in patients with stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Calcium Channel Blockers; Cardiovascular Disease | 2006 |
Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study.
Topics: Aged; Blood Pressure Determination; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug | 2007 |
Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects.
Topics: Action Potentials; Adenosine Triphosphate; Animals; Arrhythmias, Cardiac; Calcium; Calcium Channel B | 1980 |
Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cerebrovascular Disorders; Double- | 1998 |
Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris. Results from the APSIS study. The Angina Prognosis Study in Stockholm.
Topics: Adrenergic beta-Agonists; Aged; Angina Pectoris; beta-Thromboglobulin; Calcium Channel Blockers; Car | 2000 |
[Cerebrovascular effects of verapamil and prevention of headache. Clinico-experimental control].
Topics: Adult; Blood Pressure; Cardiovascular Diseases; Cerebrovascular Circulation; Clinical Trials as Topi | 1987 |
44 other studies available for verapamil and Cardiovascular Diseases
| Article | Year |
|---|---|
Analytical techniques for the determination of verapamil in biological samples and dosage forms: an overview.
Topics: Administration, Oral; Breath Tests; Calcium Channel Blockers; Cardiovascular Diseases; Drug Industry | 2019 |
Novel nonsynonymous variants associated with blood pressure control in response to antihypertensives and their impact on cardiovascular outcomes.
Topics: Cardiovascular Diseases; Factor V; Female; Glycoproteins; Humans; Immunoglobulins; Indoles; Lectins; | 2013 |
CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atenolol; Calcium Channel Blockers; Calcium Channel | 2009 |
[Seizure and non-cardiogenic pulmonary edema after intoxication].
Topics: Adult; Cardiovascular Diseases; Diagnosis, Differential; Female; Humans; Pulmonary Edema; Seizures; | 2010 |
Use of clopidogrel and calcium channel blockers and risk of major adverse cardiovascular events.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Angioplasty, Balloon, Coronary; Calcium Chan | 2012 |
Termination of refractory focal status epilepticus by the P-glycoprotein inhibitor verapamil.
Topics: Aged, 80 and over; Anticonvulsants; Aspirin; ATP Binding Cassette Transporter, Subfamily B, Member 1 | 2011 |
Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk.
Topics: Adult; Alleles; Atenolol; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, | 2012 |
Ethnic, racial, and sex-specific factors are important in cardiovascular pharmacotherapeutics.
Topics: Anti-Arrhythmia Agents; Antihypertensive Agents; Black People; Cardiovascular Agents; Cardiovascular | 2002 |
Verapamil is associated with an increased risk of cancer in the elderly: the Rotterdam study.
Topics: Aged; Calcium Channel Blockers; Cardiovascular Diseases; Cohort Studies; Cross-Sectional Studies; Fe | 2003 |
Adult hypertension: reducing cardiovascular morbidity and mortality.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Alcohol Drinking | 2005 |
The impact of diabetes or elevated fasting blood glucose on cardiovascular prognosis in patients with stable angina pectoris.
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Blood Glucose; Cardiovascular Diseases; Diabetic Angiopathi | 2005 |
Inhibition of rat platelet aggregation by Urtica dioica leaves extracts.
Topics: Animals; Aspirin; Cardiovascular Diseases; Female; Male; Mice; Phytotherapy; Plant Extracts; Plant L | 2006 |
Hypertension treatment: how important is consistency of effect?
Topics: Antihypertensive Agents; Atenolol; Blood Pressure Determination; Cardiovascular Diseases; Cohort Stu | 2007 |
Pharmacological basis for the use of Borago officinalis in gastrointestinal, respiratory and cardiovascular disorders.
Topics: Animals; Aorta; Borago; Calcium; Cardiovascular Diseases; Dose-Response Relationship, Drug; Female; | 2007 |
Welcome--the calcium channel blockers.
Topics: Adrenergic beta-Antagonists; Angina Pectoris, Variant; Arrhythmias, Cardiac; Calcium Channel Blocker | 1981 |
Therapeutic implications of slow-channel blockade in cardiocirculatory disorders.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Calcium; Cardiovascular Diseases; Coronary Disease; Diltiazem | 1980 |
Calcium channel blockers for cardiovascular disorders.
Topics: Angina Pectoris; Angina Pectoris, Variant; Arrhythmias, Cardiac; Calcium; Calcium Channel Blockers; | 1982 |
Antidotal treatment of the acute cardiovascular toxicity of verapamil.
Topics: Animals; Antidotes; Blood Pressure; Cardiac Output; Cardiovascular Diseases; Electrocardiography; He | 1984 |
Calcium channel blockers. New treatment for cardiovascular disease.
Topics: Adult; Angina Pectoris; Calcium; Calcium Channel Blockers; Cardiomyopathy, Hypertrophic; Cardiovascu | 1983 |
Calcium channel blockers: verapamil and nifedipine.
Topics: Calcium; Cardiovascular Diseases; Humans; Nifedipine; Verapamil | 1983 |
Pharmacology and electrophysiology of calcium ion antagonists.
Topics: Calcium; Cardiovascular Diseases; Gallopamil; Heart; Humans; Myocardial Contraction; Nitroglycerin; | 1980 |
Calcium blocker therapy in cardiovascular disease.
Topics: Adult; Aged; Calcium Channel Blockers; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; N | 1982 |
Calcium channel blockers: indications and limitations 1. Clinical pharmacology and use as antiarrhythmic agents.
Topics: Anti-Arrhythmia Agents; Biological Availability; Calcium; Calcium Channel Blockers; Cardiovascular D | 1982 |
The current status of calcium antagonists in cardiovascular therapy.
Topics: Calcium Channel Blockers; Cardiovascular Diseases; Humans; Nifedipine; Verapamil | 1982 |
Therapeutic uses of calcium-blocking agents:verapamil, nifedipine, and diltiazem.
Topics: Benzazepines; Calcium Channel Blockers; Cardiovascular Diseases; Diltiazem; Humans; Nifedipine; Pyri | 1981 |
Verapamil.
Topics: Cardiovascular Diseases; Humans; Verapamil | 1981 |
[Calcium inhibitors. Current indications in cardiology].
Topics: Angina Pectoris; Arrhythmias, Cardiac; Calcium; Cardiovascular Diseases; Diltiazem; Humans; Nifedipi | 1980 |
Insulin is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine.
Topics: Anesthesia; Animals; Antidotes; Blood Glucose; Cardiovascular Diseases; Disease Models, Animal; Dogs | 1993 |
Calcium channel antagonists. What do the second-generation agents have to offer?
Topics: Arteriosclerosis; Calcium Channel Blockers; Cardiovascular Diseases; Cerebrovascular Disorders; Dihy | 1994 |
The use of calcium channel blockers in general practice.
Topics: Calcium Channel Blockers; Cardiovascular Diseases; Dihydropyridines; Diltiazem; Family Practice; Fem | 1993 |
Vascular calcium overload produced by vitamin D3, in rats. Effect of treatment with SR 33805, a novel calcium entry blocker.
Topics: Animals; Aorta, Thoracic; Calcinosis; Calcium; Calcium Channel Blockers; Cardiovascular Diseases; Ch | 1995 |
Revisiting calcium channel blockers--from basic facts to clinical practice.
Topics: Aged; Calcium Channel Blockers; Cardiovascular Diseases; Diltiazem; Humans; Hypertension; Nifedipine | 1996 |
The effects of amrinone and glucagon on verapamil-induced cardiovascular toxicity in anaesthetized rats.
Topics: Amrinone; Animals; Blood Pressure; Bradycardia; Calcium Channel Blockers; Cardiovascular Diseases; D | 1996 |
Timing treatment to the rhythm of disease. A short course in chronotherapeutics.
Topics: Antineoplastic Agents; Asthma; Cardiovascular Diseases; Chronotherapy; Circadian Rhythm; Humans; Hyd | 2001 |
[Value of verapamil in long-term treatment of coronary disease, hypertension and functional disorders of the cardiovascular system].
Topics: Adult; Cardiovascular Diseases; Coronary Disease; Female; Humans; Hypertension; Male; Middle Aged; V | 1979 |
Verapamil and nifedipine in combination for the treatment of hypertrophy heart disease.
Topics: Adrenal Gland Diseases; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Humans; | 1991 |
[The effect of verapamil on adrenocortical hormone secretion].
Topics: Adrenocorticotropic Hormone; Adult; Cardiovascular Diseases; Circadian Rhythm; Dose-Response Relatio | 1990 |
Requirements for drug monitoring of verapamil: experience from an unselected group of patients with cardiovascular disease.
Topics: Adult; Aged; Aged, 80 and over; Biotransformation; Cardiovascular Diseases; Chromatography, High Pre | 1990 |
Calcium channel blocking drugs. Part II: Clinical applications.
Topics: Angina Pectoris; Angina Pectoris, Variant; Angina, Unstable; Arrhythmias, Cardiac; Calcium Channel B | 1985 |
The effect of calcium channel blocking on immune capacity of cardiovascular patients.
Topics: Adult; Aged; Calcium Channel Blockers; Cardiovascular Diseases; Female; Humans; Immunoglobulins; Imm | 1989 |
Univer, a new one-daily calcium antagonist--its role in cardiovascular disease. Proceedings of a symposium. London, 9th October 1987.
Topics: Cardiovascular Diseases; Humans; Verapamil | 1988 |
Calcium channel antagonists--cardiovascular therapy for the eighties?
Topics: Angina Pectoris; Arrhythmias, Cardiac; Calcium Channel Blockers; Cardiovascular Diseases; Diltiazem; | 1986 |
Dantrolene sodium intravenous--verapamil.
Topics: Animals; Cardiovascular Diseases; Dantrolene; Drug Interactions; Swine; Verapamil | 1985 |
Verapamil in cardiology.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Anura; Arrhythmi | 1974 |